WO2010004198A3 - Derives anticancereux de 4-oxo-l, 4-dihydro-quinolinξ, leur preparation et leur application en therapeutique - Google Patents

Derives anticancereux de 4-oxo-l, 4-dihydro-quinolinξ, leur preparation et leur application en therapeutique Download PDF

Info

Publication number
WO2010004198A3
WO2010004198A3 PCT/FR2009/051322 FR2009051322W WO2010004198A3 WO 2010004198 A3 WO2010004198 A3 WO 2010004198A3 FR 2009051322 W FR2009051322 W FR 2009051322W WO 2010004198 A3 WO2010004198 A3 WO 2010004198A3
Authority
WO
WIPO (PCT)
Prior art keywords
quinolinξ
dihydro
oxo
preparation
therapeutic use
Prior art date
Application number
PCT/FR2009/051322
Other languages
English (en)
Other versions
WO2010004198A2 (fr
Inventor
Claude Bernhart
Monsif Bouaboula
Pierre Casellas
Olivier Duclos
Jean Marc Herbert
Samir Jegham
Gary Mccort
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Priority to MX2011000329A priority Critical patent/MX2011000329A/es
Priority to CN2009801349426A priority patent/CN102149706A/zh
Priority to BRPI0915558A priority patent/BRPI0915558A2/pt
Priority to CA2730071A priority patent/CA2730071A1/fr
Priority to JP2011517201A priority patent/JP2011527321A/ja
Priority to AU2009267828A priority patent/AU2009267828A1/en
Priority to EP09784468A priority patent/EP2307401A2/fr
Publication of WO2010004198A2 publication Critical patent/WO2010004198A2/fr
Publication of WO2010004198A3 publication Critical patent/WO2010004198A3/fr
Priority to IL210458A priority patent/IL210458A0/en
Priority to US12/986,642 priority patent/US20110251194A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings

Abstract

L'invention est relative à des composés anticancéreux de formule (I):dans laquelle : • R1 représente un groupe (C3-C7)cycloalkyle ou (C1-C6)alkyle éventuellement substitué par -NRaRb; • A représente -NR2R3; • B représente -NR4R5 ou -OR6; • R6 représente H ou un groupe (C1-C4)alkyle; • Z représente N ou CH et Z' représente N ou CH si Z représente N et CH si Z représente CH; • R7 représente H ou un groupe (C1-C4)alkyle; • L représente un groupe -CH=CH-, -CH2CH2-, -CH2CH[NHC(=O)O(C1-C4)alkyle)] ou - (CH2)n-Y- (n=1-4 et Y = O ou NR8 avec R8 représente H ou un groupe (C1-C4)alkyle); • Ar représente un groupe choisi parmi :Formula (II).
PCT/FR2009/051322 2008-07-08 2009-07-06 Derives anticancereux, leur preparation et leur application en therapeutique WO2010004198A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MX2011000329A MX2011000329A (es) 2008-07-08 2009-07-06 Derivados anticancerosos de 4-oxo-l, 4-dihidro-quinolina su preparacion y su uso terapeutico.
CN2009801349426A CN102149706A (zh) 2008-07-08 2009-07-06 4-氧代-l,4-二氢-喹啉的抗肿瘤的衍生物、其制备方法和其治疗用途
BRPI0915558A BRPI0915558A2 (pt) 2008-07-08 2009-07-06 compostos anticancerígenos, processo de preparo destes, uso dos mesmos, medicamento e composição farmacêutica
CA2730071A CA2730071A1 (fr) 2008-07-08 2009-07-06 Derives anticancereux, leur preparation et leur application en therapeutique
JP2011517201A JP2011527321A (ja) 2008-07-08 2009-07-06 ４−オキソ−ｌ，４−ジヒドロ−キノリンの抗腫瘍性誘導体、それらの調製およびそれらの治療上の使用
AU2009267828A AU2009267828A1 (en) 2008-07-08 2009-07-06 Antineoplastic derivatives of 4-OXO-L, 4-dihydro-quinoline, preparation thereof, and therapeutic use thereof
EP09784468A EP2307401A2 (fr) 2008-07-08 2009-07-06 Derives anticancereux de 4-oxo-1,4-dihydro-quinoline, leur preparation et leur application en therapeutique
IL210458A IL210458A0 (en) 2008-07-08 2011-01-04 Antineoplastic derivatives of 4 - oxo - 1, 4 - dihydro - quinoline, preparation thereof, and therapeutic use thereof
US12/986,642 US20110251194A1 (en) 2008-07-08 2011-01-07 Antineoplastic derivatives, preparation thereof and therapeutic use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0803863A FR2933701A1 (fr) 2008-07-08 2008-07-08 Derives anticancereux, leur preparation et leur application en therapeutique
FR0803863 2008-07-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/986,642 Continuation US20110251194A1 (en) 2008-07-08 2011-01-07 Antineoplastic derivatives, preparation thereof and therapeutic use thereof

Publications (2)

Publication Number Publication Date
WO2010004198A2 WO2010004198A2 (fr) 2010-01-14
WO2010004198A3 true WO2010004198A3 (fr) 2010-03-04

Family

ID=40344660

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2009/051322 WO2010004198A2 (fr) 2008-07-08 2009-07-06 Derives anticancereux, leur preparation et leur application en therapeutique

Country Status (16)

Country Link
US (1) US20110251194A1 (fr)
EP (1) EP2307401A2 (fr)
JP (1) JP2011527321A (fr)
KR (1) KR20110031371A (fr)
CN (1) CN102149706A (fr)
AR (1) AR072474A1 (fr)
AU (1) AU2009267828A1 (fr)
BR (1) BRPI0915558A2 (fr)
CA (1) CA2730071A1 (fr)
FR (1) FR2933701A1 (fr)
IL (1) IL210458A0 (fr)
MX (1) MX2011000329A (fr)
RU (1) RU2011104367A (fr)
TW (1) TW201006836A (fr)
UY (1) UY31972A (fr)
WO (1) WO2010004198A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2933700B1 (fr) * 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2954943B1 (fr) * 2010-01-07 2013-03-01 Sanofi Aventis Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique
FR2955109B1 (fr) * 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
MA37821A1 (fr) * 2012-07-17 2018-02-28 Sanofi Sa Utilisation d'inhibiteurs de vegfr-3 destinés au traitement du carcinome hépatocellulaire
WO2014091265A1 (fr) 2012-12-11 2014-06-19 Aurigene Discovery Technologies Limited Dérivés de pyrimidine-2,4-diamine en tant qu'inhibiteurs de kinase

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006016067A2 (fr) * 2004-07-15 2006-02-16 Sanofi-Aventis Derives de pyrido-pyrimidine, leur preparation, leur application dans le traitement du cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006016067A2 (fr) * 2004-07-15 2006-02-16 Sanofi-Aventis Derives de pyrido-pyrimidine, leur preparation, leur application dans le traitement du cancer

Also Published As

Publication number Publication date
BRPI0915558A2 (pt) 2016-01-26
AR072474A1 (es) 2010-09-01
MX2011000329A (es) 2011-04-05
AU2009267828A1 (en) 2010-01-14
UY31972A (es) 2010-02-26
EP2307401A2 (fr) 2011-04-13
US20110251194A1 (en) 2011-10-13
FR2933701A1 (fr) 2010-01-15
RU2011104367A (ru) 2012-08-20
WO2010004198A2 (fr) 2010-01-14
CA2730071A1 (fr) 2010-01-14
JP2011527321A (ja) 2011-10-27
TW201006836A (en) 2010-02-16
CN102149706A (zh) 2011-08-10
IL210458A0 (en) 2011-03-31
KR20110031371A (ko) 2011-03-25

Similar Documents

Publication Publication Date Title
MX2007005694A (es) Nuevos derivados de betulina, preparacion y uso de los mismos.
TW200728307A (en) Novel spirochromanone derivatives
WO2007084914A3 (fr) Pyrimidines substituees par un groupe phenoxy en tant qu'antagonistes des recepteurs d’adenosine
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.
WO2008142720A3 (fr) Dérivés d'oxime quinazoline inhibiteurs des hsp90
WO2011004162A3 (fr) Composés utilisés en tant que médicaments
EP1637521A4 (fr) Nouveau compose heterocyclique tricyclique
WO2008009078A3 (fr) Dérivés de la quinazoline tri-substitués en 4,6-dl et en 2,4,6 utilisables pour traiter les infections virales
NO20080391L (no) Pyrazolbaserte LXR modulatorer
WO2006033709A3 (fr) Nouveaux derives de nucleosides
MX2010008469A (es) Pirazolopirimidinas, procedimiento para su preparacion y su uso como medicina.
NZ603896A (en) 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatement of alzheimer's disease and other forms of dementia
AR064608A1 (es) Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer.
WO2009083608A9 (fr) Quinazolines et leurs composés hétérocycliques associés, et leur utilisation thérapeutique
BRPI0409938A (pt) derivados de azetidinacarboxamida e seu uso em terapia
WO2010004198A3 (fr) Derives anticancereux de 4-oxo-l, 4-dihydro-quinolinξ, leur preparation et leur application en therapeutique
MX2009003739A (es) Derivados de hidrobenzamida como inhibidores de hsp90.
BRPI0714885B8 (pt) compostos terapêuticos e seu uso
HK1089746A1 (en) Amino alcohol derivatives, pharmaceutical compositions containing the same, and use thereof
NO20072753L (no) 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer
NO20075734L (no) Tiofenforbindelser og trombopoietin reseptoractivatorer
WO2008105526A1 (fr) Composé macrocyclique
WO2007002764A3 (fr) Oxadiazoles di-substitutees utilisees en tant que ligands des recepteurs des chimiokines cxc
WO2007010356A3 (fr) Procede pour la preparation de derives de sulfonamide
WO2009154754A3 (fr) Synthèse de dérivés de morpholine deutérés

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980134942.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09784468

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 33/KOLNP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2730071

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009784468

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011517201

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/000329

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009267828

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 20117002860

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2011104367

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2009267828

Country of ref document: AU

Date of ref document: 20090706

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0915558

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110107